@article{25647ee9b0af437cae84f92394221f06,
title = "Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines",
abstract = "Zhao et al. profile the protein responses of a large collection of cancer cell lines to drug perturbations using the RPPA platform and build a systematic protein-drug connectivity map. The integration of perturbed protein responses provides better prediction of drug sensitivity and insights into drug-resistance mechanisms and combination therapies.",
keywords = "biomarker, cancer signaling pathway, drug response, protein array",
author = "Wei Zhao and Jun Li and Chen, {Mei Ju M.} and Yikai Luo and Zhenlin Ju and Nesser, {Nicole K.} and Katie Johnson-Camacho and Boniface, {Christopher T.} and Yancey Lawrence and Pande, {Nupur T.} and Davies, {Michael A.} and Meenhard Herlyn and Taru Muranen and Zervantonakis, {Ioannis K.} and {von Euw}, Erika and Andre Schultz and Kumar, {Shwetha V.} and Anil Korkut and Spellman, {Paul T.} and Rehan Akbani and Slamon, {Dennis J.} and Gray, {Joe W.} and Brugge, {Joan S.} and Yiling Lu and Mills, {Gordon B.} and Han Liang",
note = "Funding Information: This study was supported by the National Institutes of Health ( U01CA168394 , U24CA143883 , U54HG008100 , P50CA098258 , and P50CA217685 to G.B.M., U24CA209851 and U01CA217842 to H.L. and G.B.M., P50CA221703 to H.L. and M.A.D., U24CA210950 and U24CA210949 to R.A. and G.B.M., R50CA221675 to Y.L., UL1TR003167 to A.K., and Cancer Center Support Grant P30CA016672 ); a kind gift from the Sheldon and Miriam Adelson Medical Research Foundation , Susan G. Komen ( SAC110052 ), Ovarian Cancer Research Foundation ( 545152 ), and Breast Cancer Research Foundation ( BCRF-18-110 ) to G.B.M.; the Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine to H.L.; a DoD/CDMRP award ( W81XWH-16-1-0237 ) to R.A.; Cancer Prevention and Research Institute of Texas (CPRIT) training fellowships (grant RP170593 to M.M.C. and grant RP160015 to S.V.K.); and a CPRIT grant ( RP170640 ), an OCRA collaborative research development award, and an ICI Fund Award to A.K. This work was supported by the National Cancer Institute's Office of Cancer Genomics Cancer Target Discovery and Development (CTDˆ2) initiative. The results published here are based in whole or in part upon data generated by the CTDˆ2 Network ( https://ocg.cancer.gov/programs/ctd2/data-portal ) established by the National Cancer Institute's Office of Cancer Genomics . We thank Kamalika Mojumdar for editorial assistance. Funding Information: This study was supported by the National Institutes of Health (U01CA168394, U24CA143883, U54HG008100, P50CA098258, and P50CA217685 to G.B.M. U24CA209851 and U01CA217842 to H.L. and G.B.M. P50CA221703 to H.L. and M.A.D. U24CA210950 and U24CA210949 to R.A. and G.B.M. R50CA221675 to Y.L. UL1TR003167 to A.K. and Cancer Center Support Grant P30CA016672); a kind gift from the Sheldon and Miriam Adelson Medical Research Foundation, Susan G. Komen (SAC110052), Ovarian Cancer Research Foundation (545152), and Breast Cancer Research Foundation (BCRF-18-110) to G.B.M.; the Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine to H.L.; a DoD/CDMRP award (W81XWH-16-1-0237) to R.A.; Cancer Prevention and Research Institute of Texas (CPRIT) training fellowships (grant RP170593 to M.M.C. and grant RP160015 to S.V.K.); and a CPRIT grant (RP170640), an OCRA collaborative research development award, and an ICI Fund Award to A.K. This work was supported by the National Cancer Institute's Office of Cancer Genomics Cancer Target Discovery and Development (CTD?2) initiative. The results published here are based in whole or in part upon data generated by the CTD?2 Network (https://ocg.cancer.gov/programs/ctd2/data-portal) established by the National Cancer Institute's Office of Cancer Genomics. We thank Kamalika Mojumdar for editorial assistance. G.B.M. and H.L. conceived of the project. W.Z. J.L. M.M.C. Y. Luo, J.Z. A.S. S.V.K. A.K. R.A. G.B.M. and H.L. contributed to the data analysis. N.K.N. K.J.C. C.T.B. Y. Lawrence, N.T.P. M.A.D. M.H. T.M. I.K.Z. E.V.E. P.T.S. D.J.S. J.S.B. J.W.G. Y. Lu, and G.B.M. contributed to the experiments. M.M.C. and J.L. implemented the web portal. W.Z. J.L. M.M.C. Y. Luo, G.B.M. and H.L. wrote the manuscript, with input from other authors. H.L. supervised the whole project. R.A. is a bioinformatics consultant for the University of Houston. G.B.M. is on the scientific advisory board or a consultant for AstraZeneca, ImmunoMet, Lilly, Nuevolution, PDX Pharmaceuticals, Symphogen, and Tarveda; has stock options with Catena Pharmaceuticals, ImmunoMet, SignalChem, and Tarveda; and has licensed technologies to Myriad and Nanostring. H.L. is a shareholder and scientific advisor of Precision Scientific Ltd. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = dec,
day = "14",
doi = "10.1016/j.ccell.2020.10.008",
language = "English (US)",
volume = "38",
pages = "829--843.e4",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",
}